盲人复明，马斯克Neuralink联创实现人工视觉里程碑

Core Insights - The article highlights a groundbreaking advancement in artificial vision technology, specifically the PRIMA retinal implant, which has successfully restored functional central vision to a 70-year-old woman after 15 years of blindness [1][3][5]. Group 1: Technology Overview - PRIMA is a world-first artificial vision research project that utilizes a photovoltaic retinal implant to restore vision by acting as a substitute for light-sensitive cells [13][15]. - The device consists of a small photovoltaic retinal implant (2mm x 2mm x 30μm) and special glasses that capture images and convert them into infrared beams, which the implant then processes to stimulate remaining retinal neurons [15][19]. - The system has shown promising results, with 84% of participants recovering functional central vision and 80% achieving a significant improvement in visual acuity [16][19]. Group 2: Clinical Trials and Results - The study involved 38 patients from 17 clinical sites across five countries, with 32 completing the final evaluation [16]. - Results indicated an average improvement of 25.5 letters on the standard vision test, equating to an increase of two lines on the vision chart [16]. - Despite some initial adverse reactions, 95% of patients experienced symptom resolution within two months, and overall benefits outweighed the risks associated with the implant surgery [19]. Group 3: Future Developments - PRIMA has been submitted for regulatory approval in Europe and is undergoing the FDA approval process in the U.S., with plans for a commercial launch in 2024 [21]. - The research team is also working on next-generation implants and glasses to enhance visual performance, aiming for smaller pixels and color vision capabilities [24]. - The company behind PRIMA, Science Corporation, was co-founded by Max Hodak, a former co-founder of Neuralink, and focuses on neuroengineering and brain-machine interface technologies [25][29].